Laurent Meijer
Impact in
- Toxicology top 0.05%
- Oncology top 0.1%
- Cancer-related Molecular Pathways
Papers in
-
- Cancer therapeutics and mechanisms 34
- 14-3-3 protein interactions 20
-
- Quinazolinone synthesis and applications 49
- Synthesis and Biological Evaluation 37
- Synthesis and Reactivity of Heterocycles 25
- Co-authors
- Paul Greengard (12 shared papers)Olivier Lozach (77 shared papers)Sophie Leclerc (14 shared papers)Ali H. Brivanlou (3 shared papers)Léandros Skaltsounis (6 shared papers)Maryse Leost (20 shared papers)Noboru Sato (1 shared paper)Marie Knockaert (14 shared papers)
- Journals
- Journal of Medicinal Chemistry (31 papers)European Journal of Medicinal Chemistry (25 papers)Bioorganic & Medicinal Chemistry Letters (16 papers)Bioorganic & Medicinal Chemistry (16 papers)Journal of Biological Chemistry (11 papers)
- Partner nations
- FranceUnited StatesGermany
In The Last Decade
Laurent Meijer
368 papers receiving 26.7k citations
Laurent Meijer's Hit Papers
Peers
Comparison fields: 5 of 159
- Toxicology 829
- Oncology 6.0k
- Cell Biology 3.8k
- Organic Chemistry 6.9k
- Molecular Biology 14.9k
Countries citing papers authored by Laurent Meijer
This map shows the geographic impact of Laurent Meijer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laurent Meijer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laurent Meijer more than expected).
Fields of papers citing papers by Laurent Meijer
This network shows the impact of papers produced by Laurent Meijer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laurent Meijer. The network helps show where Laurent Meijer may publish in the future.
Co-authors
The 25 scholars most cited alongside Laurent Meijer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 371 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor Hit paper breakdown → | 2003 | 1659 |
| 2 | Biochemical and Cellular Effects of Roscovitine, a Potent and Selective Inhibitor of the Cyclin‐Dependent Kinases cdc2, cdk2 and cdk5 Hit paper breakdown → | 1997 | 1194 |
| 3 | Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases Hit paper breakdown → | 1999 | 684 |
| 4 | Exploiting Chemical Libraries, Structure, and Genomics in the Search for Kinase Inhibitors Hit paper breakdown → | 1998 | 678 |
| 5 | GSK-3-Selective Inhibitors Derived from Tyrian Purple Indirubins Hit paper breakdown → | 2003 | 676 |
| 6 | Indirubins Inhibit Glycogen Synthase Kinase-3β and CDK5/P25, Two Protein Kinases Involved in Abnormal Tau Phosphorylation in Alzheimer's Disease Hit paper breakdown → | 2001 | 636 |
| 7 | Inhibition of Cyclin‐Dependent Kinases by Purine Analogues Hit paper breakdown → | 1997 | 622 |
| 8 | Inhibition of Cyclin‐Dependent Kinases by Purine Analogues Hit paper breakdown → | 1994 | 561 |
| 9 | Pharmacological inhibitors of glycogen synthase kinase 3 Hit paper breakdown → | 2004 | 501 |
| 10 | cdc2 is a component of the M phase-specific histone H1 kinase: Evidence for identity with MPF Hit paper breakdown → | 1988 | 488 |
| 11 | 1999 | 469 | |
| 12 | 2002 | 446 | |
| 13 | 2000 | 424 | |
| 14 | 2000 | 373 | |
| 15 | 2000 | 330 | |
| 16 | 2004 | 326 | |
| 17 | 2006 | 299 | |
| 18 | 1999 | 290 | |
| 19 | 2003 | 290 | |
| 20 | 1989 | 268 |
About Laurent Meijer
Laurent Meijer is a scholar working on Molecular Biology, Organic Chemistry, Oncology, Cell Biology and Public Health, Environmental and Occupational Health, having authored 371 papers that have together received 27.5k indexed citations. Recurring topics across this work include Cancer-related Molecular Pathways (91 papers), Microtubule and mitosis dynamics (58 papers), Quinazolinone synthesis and applications (49 papers), Synthesis and Biological Evaluation (37 papers), Cancer therapeutics and mechanisms (34 papers), Synthesis and Reactivity of Heterocycles (25 papers), Bioactive Compounds and Antitumor Agents (24 papers) and 14-3-3 protein interactions (20 papers). The work is most often cited by research in Toxicology (829 citations), Oncology (6.0k citations), Cell Biology (3.8k citations), Organic Chemistry (6.9k citations) and Molecular Biology (14.9k citations). Laurent Meijer has collaborated with scholars based in France, United States and Germany. Frequent co-authors include Paul Greengard, Olivier Lozach, Sophie Leclerc, Ali H. Brivanlou, Léandros Skaltsounis, Maryse Leost, Noboru Sato, Marie Knockaert, Annie Borgne and Yoan Ferandin. Their work appears in journals such as Journal of Medicinal Chemistry, European Journal of Medicinal Chemistry, Bioorganic & Medicinal Chemistry Letters, Bioorganic & Medicinal Chemistry and Journal of Biological Chemistry.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.